These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21719260)

  • 1. [Idiopathic nephrotic syndrome in children: from corticosteroids to rituximab].
    Deschênes G
    Arch Pediatr; 2011 Aug; 18(8):843-5. PubMed ID: 21719260
    [No Abstract]   [Full Text] [Related]  

  • 2. Repeated course of rituximab for treatment of nephrotic syndrome in patients with chronic GVHD.
    Mellon-Reppen S; Ratanatharathorn V; Cronin S; Uberti JP
    Bone Marrow Transplant; 2010 Dec; 45(12):1758-9. PubMed ID: 20383208
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab in patients with the steroid-resistant nephrotic syndrome.
    Bagga A; Sinha A; Moudgil A
    N Engl J Med; 2007 Jun; 356(26):2751-2. PubMed ID: 17596616
    [No Abstract]   [Full Text] [Related]  

  • 4. [Beneficial effects of rituximab in the treatment of refractory nephrotic syndrome].
    Imai E
    Nihon Jinzo Gakkai Shi; 2012; 54(5):593-7. PubMed ID: 22991838
    [No Abstract]   [Full Text] [Related]  

  • 5. Rituximab treatment for recurrence of nephrotic syndrome in a pediatric patient after renal transplantation for congenital nephrotic syndrome of Finnish type.
    Chaudhuri A; Kambham N; Sutherland S; Grimm P; Alexander S; Concepcion W; Sarwal M; Wong C
    Pediatr Transplant; 2012 Aug; 16(5):E183-7. PubMed ID: 21672106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in steroid-dependent nephrotic syndrome.
    El Koumi M
    Iran J Kidney Dis; 2013 Nov; 7(6):502-6. PubMed ID: 24241100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ofatumumab for rituximab-resistant nephrotic syndrome.
    Basu B
    N Engl J Med; 2014 Mar; 370(13):1268-70. PubMed ID: 24670185
    [No Abstract]   [Full Text] [Related]  

  • 8. [Idiopathic thrombocytopenic purpura (ITP) in children].
    Rajantie J
    Duodecim; 2011; 127(19):2081-6. PubMed ID: 22073540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurological picture. Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange.
    Sempere AP; Feliu-Rey E; Sanchez-Perez R; Nieto-Navarro J
    J Neurol Neurosurg Psychiatry; 2013 Dec; 84(12):1338-9. PubMed ID: 23804236
    [No Abstract]   [Full Text] [Related]  

  • 10. Rituximab followed by mycophenolate mofetil in children with IgM nephropathy.
    Gu J; Xia Y; Mao J; Fu H; Liu A
    Indian Pediatr; 2012 Oct; 49(10):831-3. PubMed ID: 23144102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for early relapse during maintenance therapy after a single infusion of rituximab in children with steroid-dependent nephrotic syndrome.
    Fujinaga S; Hirano D
    Pediatr Nephrol; 2014 Mar; 29(3):491-2. PubMed ID: 24240472
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of rituximab in MCNS: a role for IL-13 suppression?
    Kim JE; Park SJ; Ha TS; Shin JI
    Nat Rev Nephrol; 2013 Sep; 9(9):551. PubMed ID: 23958716
    [No Abstract]   [Full Text] [Related]  

  • 13. Rituximab for steroid-dependent nephrotic syndrome.
    Beco A; Castro-Ferreira I; Coentrao L; Neto R; Sampaio S; Pestana M
    Clin Nephrol; 2010 Oct; 74(4):308-10. PubMed ID: 20875384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for childhood refractory nephrotic syndrome.
    Iijima K
    Pediatr Int; 2011 Oct; 53(5):617-621. PubMed ID: 21771179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New treatments for Idiopathic Nephrotic Syndrome].
    Guigonis V
    Arch Pediatr; 2009 Jun; 16(6):802-4. PubMed ID: 19541177
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab therapy for deep toe ulcer with microscopic polyangiitis refractory to corticosteroids and cyclophosphamide.
    Kawakami T; Okano T; Soma Y
    J Dermatol; 2014 Feb; 41(2):191-2. PubMed ID: 24471464
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab for refractory cases of childhood nephrotic syndrome.
    Kari JA; El-Morshedy SM; El-Desoky S; Alshaya HO; Rahim KA; Edrees BM
    Pediatr Nephrol; 2011 May; 26(5):733-7. PubMed ID: 21279725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab.
    Guiard E; Karras A; Plaisier E; Duong Van Huyen JP; Fakhouri F; Rougier JP; Noel LH; Callard P; Delahousse M; Ronco P
    Clin J Am Soc Nephrol; 2011 Jul; 6(7):1609-16. PubMed ID: 21700823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe steroid-dependent idiopathic angioedema with response to rituximab.
    Ghazan-Shahi S; Ellis AK
    Ann Allergy Asthma Immunol; 2011 Oct; 107(4):374-6. PubMed ID: 21962102
    [No Abstract]   [Full Text] [Related]  

  • 20. Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?
    Smith GC
    Pediatr Nephrol; 2007 Jun; 22(6):893-8. PubMed ID: 17310362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.